ESTRO 36 Programme book and exhibition guide

INTERDISCIPLINARY RADIOBIOLOGY CLINICAL BRACHYTHERAPY PHYSICS RTT YOUNG

SATURDAY 6 MAY 2017

SYMPOSIUM The optimal approach to treat oligometastastic disease: different ways to handle an indication quickly gaining acceptance 14:45 - 16:00 | AUDITORIUM Radical radiotherapy in the form of stereotactic body radiotherapy (SBRT) has become a routine practice in many institutions for patients with oligo-metastatic disease. This rapid development was observed despite the lack prospective evidence proofing the value of SBRT, despite oligo-oligometastasis is poorly defined and despite patient selection criteria are still limited. This symposium summarises the challenges of the oligo-metastatic concept, the role of radiotherapy and surgery and appropriate patient selection for these local treatment options. A clinical approach to the abscopal effect – investigated in many pre-clinical studies but observed rarely in daily clinical practice – is presented and discussed.

Chair: M. Guckenberger (Switzerland) Co-chair: I. Ratosa (Slovenia)

14:45 > Clinical approach to abscopal effects Speaker: P.C. Lara Jimenez (Spain)

SP-0097

15:03 > What is the purpose of surgical metastasectomy and do we achieve it? Speaker: T. Treasure (UK) 15:21 > What is the indication and what is the aim of clinical treatment: radiotherapy Speaker: E. Lartigau (France)

SP-0098

SP-0099

15:39 > Oligometastastic cancer: a therapeutic challenge Speaker: K. Van der Hoeven (The Netherlands)

SP-0100

SYMPOSIUMWITH PROFFERED PAPERS Targeting tumour heterogeneity 14:45 - 16:00 | SCHUBERT

It is well known that a tumour is not a homogeneous collection of malignant cells. In contrast to that a tumour lump consist of e.g. areas with cells of different differentiation grade and different oxygenation caused by development of multiple subclones at the same time. These subclones are often spatially segregated. An example is prostate cancer with areas of different Gleason patterns and oxygenation as has been shown by BOLD-MRI. Focal treatment of prostate cancer has evolved to treat only the dominant intraprostatic lesion(s) leaving out non-significant disease. One reason to differentiate treatment between areas of the same tumour is that genotypes and phenotypes that evolve often differ between primary tumours and metastases. The resulting subclonal heterogeneity complicates effective targeting. New challenges are arising for targeting

Programme and Exhibition Guide | SCIENTIFIC PROGRAMME

87